TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03890796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Scheduling
Description: AS is strategy for behavioral activation that has also been used with success in people with dementia, after the training of their caregivers. A certified occupational therapist will train up the caregivers of dementia in conducting AS activities for participants in experimental group

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Educational
Description: A serial of dementia care education program with a weekly theme of topics like: importance of exercise and healthy eating, sleep management, counselling, acceptance therapy, commitment therapy, reminiscence therapy.
Study: NCT00047411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Resuscitation
Description: Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic External Defibrillation
Description: Use the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
Study: NCT01879020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 1mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 2.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 25mg
Study: NCT03890796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational
Description: A serial of dementia care education program with a weekly theme of topics like: importance of exercise and healthy eating, sleep management, counselling, acceptance therapy, commitment therapy, reminiscence therapy.
Study: NCT02914990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-15086
Description: BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.
Study: NCT01879020

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (TA-8995 1mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (TA-8995 2.5mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (TA-8995 5mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (TA-8995 10mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (TA-8995 25mg)
Study: NCT01936038

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CPAP
Description: CPAP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Airway Toning for Improve the Compliance of CPAP
Description: Upper Airway Toning for Improve the Compliance of CPAP
Study: NCT00904254

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EP 1645/Solution For Injection, 99mTC
Description: (Fab-fragment of Anti-human CD4,technetium-99m)
Study: NCT03270722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLIP topography
Description: During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLIP topography
Description: During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
Study: NCT02437747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP + Aloe
Description: Scaling and root planing along with aloe vera application was done

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SRP
Description: Scaling and root planing was done
Study: NCT04503603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to lanadelumab IV infusion on Day 1 followed by Day 4.
Study: NCT02955641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Disodium Phosphate 0.1%
Description: four drops a day for four days after LPI treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Disodium Phosphate 0.1%
Description: four drops a day for four days after LPI treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac 0.1%
Description: four drops a day for four days after LPI treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac 0.1%
Description: four drops a day for four days after LPI treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethylcellulose 0.19%
Description: four drops a day for four days after LPI treatment
Study: NCT00159406

Intervention type: OTHER
Intervention: Registry and Database
Description: Data Collection
Study: NCT00984568

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab intravenous infusion at a dose of 5 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab intravenous infusion at a dose of 5 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-aminosalicylic acid
Description: 5-ASA administered orally at a dose of 2 g/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: AZA administered orally at a dose of 2.0-2.5 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
Study: NCT02964507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: GSK525762 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: GSK525762 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant will be administered.
Study: NCT02783469

Intervention type: GENETIC
Intervention: Identification of genetic causes of diabetic neuropathic pain

Intervention type: GENETIC
Intervention: Identification of genetic causes of diabetic neuropathic pain
Study: NCT03270722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLIP topography
Description: During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
Study: NCT01987674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-meal protein drink
Study: NCT03270722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Endoscopy
Description: A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Endoscopy
Description: A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Endoscopy
Description: A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
Study: NCT02917590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task obstacle crossing training
Description: Obstacle crossing simultaneously a color word stroop task training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Single-task obstacle crossing training
Description: Obstacle crossing training
Study: NCT03021902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV amino acids
Description: IV amino acids delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day as a combination of amino acid infusion plus standard feeding.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-bed cycle ergometry exercise
Description: In-bed cycle ergometry exercise delivered in 45-minute sessions once-daily 5 days per week according to a detailed specific protocol that includes a safety check in combination with vigorous verbal encouragement from trained research staff delivering the intervention to promote active cycling.~Cycling is protocolized to provide graduated increases in resistance during each session and between daily sessions. Cycling will continue through ICU discharge or 21 calendar days after randomization. The intervention will specifically occur during ICU stay.
Study: NCT02774590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.
Study: NCT02561156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.
Study: NCT03939208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRISC

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAU
Study: NCT02515240

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: 23 valent pneumococcal polysaccharide vaccine in Healthy adults.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: 23 valent pneumococcal polysaccharide vaccine in Healthy adults.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: 23 valent pneumococcal polysaccharide vaccine in Healthy adults.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: 23 valent pneumococcal polysaccharide vaccine in Healthy adults.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: 23 valent pneumococcal polysaccharide vaccine in Healthy adults.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: 23 valent pneumococcal polysaccharide vaccine in Healthy adults.
Study: NCT02582684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Participants were prescribed 50 mg of DTG orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Participants were prescribed 300 mg of 3TC orally daily.
Study: NCT01334827

Intervention type: OTHER
Group type: OTHER
Intervention: high volume gel
Description: 4 mL HEC

Intervention type: OTHER
Group type: OTHER
Intervention: low volume gel
Description: 2 mL HEC

Intervention type: OTHER
Group type: OTHER
Intervention: vaginal film
Description: 1 x 2 intravaginal quick-dissolving film
Study: NCT03180684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: One milliliter (1 mL) VGX-3100 injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: One milliliter (1 mL) VGX-3100 injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24.
Study: NCT02955641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethylcellulose 0.19%
Description: four drops a day for four days after LPI treatment
Study: NCT03180684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% Cream
Description: Participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
Study: NCT01987674

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water drink
Study: NCT01857154

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronized Calcium Carbonate
Description: Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronized Calcium Carbonate
Description: Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Micronized Calcium Carbonate
Description: Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Micronized Calcium Carbonate
Description: Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: All subjects in the study cohort will be administered 800 IU Vitamin D3.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: All subjects in the study cohort will be administered 800 IU Vitamin D3.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: All subjects in the study cohort will be administered 800 IU Vitamin D3.
Study: NCT02955641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethylcellulose 0.19%
Description: four drops a day for four days after LPI treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethylcellulose 0.19%
Description: four drops a day for four days after LPI treatment
Study: NCT01839279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Study: NCT04138186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2.0g G-PUR®, oral administration
Description: tid for 12 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, oral administration
Description: tid for 12 weeks
Study: NCT03180684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000
Description: IM injection of VGX-3100 was followed by EP with the CELLECTRA™ 2000 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000
Description: IM injection of VGX-3100 was followed by EP with the CELLECTRA™ 2000 device.
Study: NCT00957593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Continuation of oxytocin once in active labor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin discontinuation
Description: Oxytocin will be stopped once in active labor
Study: NCT02548728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin Spray
Description: 10 insufflations (40IU of oxytocin total) given three times on day of enrollment and then twice daily for 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
Study: NCT02751931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Participants received initial dose of 25 mg of mirabegron PED25 orally once daily. At weeks 2, 4 or 8, participants were up-titrated to PED50 based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT. Participants with a body weight \>=35 kg received mirabegron tablets or body weight \<35 kg received mirabegron oral suspension. At week 24, participants on mirabegron oral suspension could switch to tablets if the body weight became \>=35 kg or participants on mirabegron tablets could switch to oral suspension if the body weight became \<35 Kg or participants could switch to either of the dosage form for acceptability reasons after sponsor's prior approval and on a case-by-case basis. Mirabegron extended-release granules were reconstituted with water to prepare a mirabegron oral suspension of 8 mg/mL. Administration was via an oral syringe with a sip of water afterwards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Participants received initial dose of 25 mg of mirabegron PED25 orally once daily. At weeks 2, 4 or 8, participants were up-titrated to PED50 based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT. Participants with a body weight \>=35 kg received mirabegron tablets or body weight \<35 kg received mirabegron oral suspension. At week 24, participants on mirabegron oral suspension could switch to tablets if the body weight became \>=35 kg or participants on mirabegron tablets could switch to oral suspension if the body weight became \<35 Kg or participants could switch to either of the dosage form for acceptability reasons after sponsor's prior approval and on a case-by-case basis. Mirabegron extended-release granules were reconstituted with water to prepare a mirabegron oral suspension of 8 mg/mL. Administration was via an oral syringe with a sip of water afterwards.
Study: NCT01986933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nemolizumab (CIM331)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nemolizumab (CIM331)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nemolizumab (CIM331)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nemolizumab (CIM331)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nemolizumab (CIM331)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo